FDA proposes to withdraw approval for Salerno's liquid cholesterol medicationThe FDA's drug evaluation department proposed withdrawing approval for Salerno Pharmaceuticals' liquid simvastatin oral suspension, citing missing annual reports.Nov 17, 2026·3 sourcesStatinsFDA regulatory processLDL cholesterolDrug Policy, Pricing & Approval00